中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
19期
1922-1924
,共3页
雷帕霉素%碘-125%非小细胞肺癌%联合应用%临床研究
雷帕黴素%碘-125%非小細胞肺癌%聯閤應用%臨床研究
뢰파매소%전-125%비소세포폐암%연합응용%림상연구
rapamycin%iodine-125%non-small cell lung cancer%combined application%clinical research
目的 评价雷帕霉素联合碘 -125 ( I125 )治疗中晚期非小细胞肺癌(NSCLC)的临床疗效.方法 92例NSCLC患者随机分为对照组和试验组,每组46例,对照组按照粒子植入治疗计划系统( TPS)制定粒子治疗计划,在电子计算机断层扫描(CT)引导下将I125植入肿瘤内,处方剂量为90 Gy. 试验组在此基础上加用雷帕霉素,每次2 mg,每天1次,3周为1个疗程,治疗4个疗程. 治疗结束后4周进行CT扫描,参照实体瘤疗效评价标准( RECIST)进行疗效评价;观察并记录患者治疗后的卡式体能状态评分(KPS)、体重指数(BMI)和疾病进展时间( TTP );记录2 组的生存期和不良反应. 结果 试验组客观缓解率(43.48%)显著高于对照组(30.43%,P<0.05);2组患者治疗后KPS、BMI 和TTP较治疗前升高(P<0.01,P<0.05,P<0.01),试验组治疗后上述指标显著高于对照组(P<0.05,P<0.01,P<0.05);试验组中位生存时间为17.03个月, 1年生存率为74.52%,显著高于对照组的13.16个月和63.35%( P<0.05 ). 2组患者在胃肠道不适、肝肾功能损伤、贫血等方面差异无统计学意义( P>0.05 ).结论 雷帕霉素联合I125粒子植入联合应用,能有效提高中晚期NSCLC患者的疗效,提高患者KPS、BMI及TTP水平,延长患者生存时间,不良反应少.
目的 評價雷帕黴素聯閤碘 -125 ( I125 )治療中晚期非小細胞肺癌(NSCLC)的臨床療效.方法 92例NSCLC患者隨機分為對照組和試驗組,每組46例,對照組按照粒子植入治療計劃繫統( TPS)製定粒子治療計劃,在電子計算機斷層掃描(CT)引導下將I125植入腫瘤內,處方劑量為90 Gy. 試驗組在此基礎上加用雷帕黴素,每次2 mg,每天1次,3週為1箇療程,治療4箇療程. 治療結束後4週進行CT掃描,參照實體瘤療效評價標準( RECIST)進行療效評價;觀察併記錄患者治療後的卡式體能狀態評分(KPS)、體重指數(BMI)和疾病進展時間( TTP );記錄2 組的生存期和不良反應. 結果 試驗組客觀緩解率(43.48%)顯著高于對照組(30.43%,P<0.05);2組患者治療後KPS、BMI 和TTP較治療前升高(P<0.01,P<0.05,P<0.01),試驗組治療後上述指標顯著高于對照組(P<0.05,P<0.01,P<0.05);試驗組中位生存時間為17.03箇月, 1年生存率為74.52%,顯著高于對照組的13.16箇月和63.35%( P<0.05 ). 2組患者在胃腸道不適、肝腎功能損傷、貧血等方麵差異無統計學意義( P>0.05 ).結論 雷帕黴素聯閤I125粒子植入聯閤應用,能有效提高中晚期NSCLC患者的療效,提高患者KPS、BMI及TTP水平,延長患者生存時間,不良反應少.
목적 평개뢰파매소연합전 -125 ( I125 )치료중만기비소세포폐암(NSCLC)적림상료효.방법 92례NSCLC환자수궤분위대조조화시험조,매조46례,대조조안조입자식입치료계화계통( TPS)제정입자치료계화,재전자계산궤단층소묘(CT)인도하장I125식입종류내,처방제량위90 Gy. 시험조재차기출상가용뢰파매소,매차2 mg,매천1차,3주위1개료정,치료4개료정. 치료결속후4주진행CT소묘,삼조실체류료효평개표준( RECIST)진행료효평개;관찰병기록환자치료후적잡식체능상태평분(KPS)、체중지수(BMI)화질병진전시간( TTP );기록2 조적생존기화불량반응. 결과 시험조객관완해솔(43.48%)현저고우대조조(30.43%,P<0.05);2조환자치료후KPS、BMI 화TTP교치료전승고(P<0.01,P<0.05,P<0.01),시험조치료후상술지표현저고우대조조(P<0.05,P<0.01,P<0.05);시험조중위생존시간위17.03개월, 1년생존솔위74.52%,현저고우대조조적13.16개월화63.35%( P<0.05 ). 2조환자재위장도불괄、간신공능손상、빈혈등방면차이무통계학의의( P>0.05 ).결론 뢰파매소연합I125입자식입연합응용,능유효제고중만기NSCLC환자적료효,제고환자KPS、BMI급TTP수평,연장환자생존시간,불량반응소.
Objective To evaluate the clinical effect on rapamycin com-bined with iodine -125 in the treatment of advanced non -small cell lung cancer.Methods A total of 92 patients with advanced non -small cell lung cancer were randomly divided into control group (46 cases) and treatment group ( 46 cases ) .The iodine 125 particle implantation was performed according to the treatment planning system ( TPS ) formulation by CT guided and the dosage was 90 Gy.The treatment group were trea-ted with rapamycin(2 mg per time, qd) on the basis of control group. Three weeks is one course , patients all treated for four courses .The eva-luation of treatment effect was confirmed by CT scans after the four courses of treatment.The efficacy was evaluated by response evaluation criteria in solid tumors reference ( RECIST ) criteria.The changes of KPS, BMI and TTP were recorded and the survival time , adverse reactions were compared between the two groups .Results The objective response rate was 43.48% in the treatment group , significantly higher than that in control group, which was 30.43%(P<0.05).The KPS, BMI and TTP of the two groups increased than before treatment , and treatment group was more significant ( P<0.05 , P<0.01 ) .The median survival time ( 17.03 months) and one year survival rate (74.52%) in treatment group were higher than those in control group (13.16 months, 63.35%, P<0.05).The adverse reactions of gastrointestinal tract , liver and kidney dysfunction and anemia in the two groups had no statistical differences ( P>0.05 ) .Conclusion Rapamycin combined with iodine -125 can improve the clinical effects of advanced non -small cell lung cancer and improve the levels of KPS ,BMI and TTP, and also extend the survival period of patient and decrease adverse reactions .
